Management of relapsed or refractory follicular lymphoma patients in daily practice – a French non-interventional study-Reference-Cited by-同舟云学术

Management of relapsed or refractory follicular lymphoma patients in daily practice – a French non-interventional study

Published:2018-02-28 Issue:10 Volume:59 Page:2485-2488
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Feugier Pierre¹,Brice Pauline²,Maynadié Marc³,Franchi-Rezgui Patricia⁴,Hacini Maya⁵,Laurent Guy⁶,Suc Etienne⁷,Fitoussi Olivier⁸,Solal-Celigny Philippe⁹,Damaj Ghandi¹⁰,Haioun Corinne¹¹,Leconte Pierre¹²,Lazreg Fatima¹²,Boissard Frédéric¹²,Pau David¹²,Salles Gilles¹³

Affiliation:

1. Department of Hematology, CHU of Nancy, Vandoeuvre-lès-Nancy, France;

2. Department of Hematology, Hospital Saint-Louis APHP, University of Paris VII, Paris, France;

3. Department of Biolofical Hematology, CHU of Dijon, Dijon, France;

4. Department of Hematology, Hospital Cochin APHP, University of Paris VI, Paris, France;

5. Department of Hematology, Hospital Center of Chambéry, Chambéry, France;

6. Department of Hematology, Hospital Purpan, Toulouse, France;

7. Department of Hematology, Clinic of Pont de Chaume, Montauban, France;

8. Department of Hematology, Polyclinic Bordeaux Nord Aquitaine, Bordeaux, France;

9. Department of Hematology, Western Cancer Institute, Nantes, France;

10. Department of Hematology, CHU of Caen, Caen, France;

11. Department of Hematology, Hospital Henri Mondor, Créteil, France;

12. Roche, Boulogne-Billancourt, France;

13. Department of Hematology, Civil Hospices of Lyon, University Claude Bernard Lyon-1, Pierre Bénite, France

Funder

Roche, France

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2018.1434878

Reference13 articles.

1. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial

2. Intensive therapies in follicular non-Hodgkin lymphomas

3. B-cell receptor pathway modulators in NHL

4. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The investigation and management of follicular lymphoma;British Journal of Haematology;2020-06-24

2. Choosing the appropriate salvage therapy for B-cell non-Hodgkin lymphoma;Expert Opinion on Pharmacotherapy;2018-09-10